The 2026 Buyer's Guide to AI Pentesting for Medical Devices

Most medical device penetration testing was bought to satisfy a submission. In 2026 the gap between being tested and being defended is wider than it has ever been: AI-driven discovery finds candidate vulnerabilities in binaries at machine speed, regulators expect a program that runs through the device's supported life, and the models that do the most capable discovery work are gated behind vetting a manufacturer cannot complete on the side.

This guide resets the evaluation criteria, walks through the three testing models buyers actually encounter, explains what a real pipeline is and why the model inside it is interchangeable, and makes the case that the purchase is two things: discovery and the management platform that turns discovery into proof.

What is inside

• Why the way manufacturers buy testing is broken
• Why continuous testing wins, and what a real subscription includes
• The three testing models manufacturers actually encounter
• What a real pipeline is, and why the model is a component
• Model access is now a procurement question
• Why building it yourself means building a software product
• The purchase is two things: discovery and management
• The evaluation criteria that matter in 2026
• Questions to ask vendors, which most buyers do not
• What effective testing looks like operationally
• Common buying mistakes in 2026
• How to apply this inside your organization
• Glossary and evaluation checklist

Key takeaways

• AI made vulnerability discovery cheap. Validation, prioritization, and proof of remediation are now the scarce work, and they are what a manufacturer is actually buying.
• A point-in-time pentest was designed to produce a submission artifact. FDA's postmarket expectation is a continuous program, and the two are priced, scoped, and evidenced differently.
• A real AI-driven pipeline is a harness around a model, with the test plan derived from the device before the first packet is sent. The model is a swappable component, so judge the harness.
• The most capable cyber models of 2026 are reserved for verified defenders, and most manufacturers will never complete that vetting. Who holds the access, and under what controls, is a procurement question.
• Building a pipeline internally means building and maintaining a software product. A prompt that works on Tuesday is the easy part.
• Discovery without management is a liability. Require the platform that verifies exploitability on the device, dismisses the rest with evidence, and proves the fix.

Who it is for

Product security and cybersecurity leads who own the testing budget, regulatory affairs teams who have to defend the evidence in a 510(k), De Novo, or PMA, CISOs and engineering leaders who must absorb AI-scale vulnerability volume without adding headcount, and anyone who has been asked whether the company should build its own AI-driven pipeline.